Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis‐associated interstitial lung disease

The benefit of rituximab (RTX) for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has been shown in previous clinical trials. However, predictors of RTX efficacy have not been clarified. We investigated whether B‐cell responsiveness to RTX is related to therapeutic effect. Ten SSc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of dermatology 2022-01, Vol.49 (1), p.179-183
Hauptverfasser:	Ebata, Satoshi, Yoshizaki, Ayumi, Fukasawa, Takemichi, Yoshizaki‐Ogawa, Asako, Asano, Yoshihide, Kashiwabara, Kosuke, Oba, Koji, Sato, Shinichi
Format:	Artikel
Sprache:	eng
Schlagworte:	B cells B-Lymphocytes Clinical trials forced vital capacity Humans Immunotherapy Lung Lung diseases Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - etiology Lymphocytes B Monoclonal antibodies Peripheral blood Retrospective Studies Rituximab Rituximab - therapeutic use Scleroderma Scleroderma, Systemic - complications Scleroderma, Systemic - drug therapy Systemic sclerosis systemic sclerosis‐associated interstitial lung disease Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!